Charity Breast Cancer Now has described the failure to negotiate a fair price of Enhertu as “utterly heartbreaking”.

The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) says that talks with the makers ...

AZ and Daiichi Sankyo have said that NICE's decision on Enhertu exposes how new methods and processes the agency uses to ...

The phase 3 MK-3475A-D77 trial tested subcutaneous and intravenous Keytruda given every six weeks in combination with ...

Breast cancer drug blocked for NHS use as price talks break down for third time - Nice said it was ‘extremely disappointed’ ...

Breast cancer patients in England and Wales will not have access to the drug after pricing negotiations failed between NICE and drugmakers.

Merck said on Tuesday a study showed its injectable version of cancer drug Keytruda was not inferior to the currently ...

Women with incurable breast cancer in England and Wales will not be offered a life-extending drug on the national health service after talks between the NHS spending watchdog and its manufacturer ...

Merck's Keytruda sales rose 17.2% YoY to $7.43 billion. Find out why MRK stock's strong fundamentals and high dividend yield ...

Chubb Group of Insurance Companies, Colonial Surety Company, Crum & Forster, CVS Caremark,Daiichi Sankyo, Inc., Endurance ...

Although AstraZeneca, Daiichi Sankyo and England’s drug cost watchdog have spent months trying to hash out a fair price for ...